Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), developer of a next generation antibiotic, has appointed a vice president of clinical development.
Stephanie Noviello, who joins from Bristol-Myers Squibb, will report into chief medical officer David Huang.
READ: Motif Bio to make two poster presentations to key conference
She will be a key contributor to the European marketing authorisation Application submission for iclaprim, Motif's lead drug, which successfully negotiated two phase III clinical trials.
Before Bristol-Myers Noviello was with Schering-Plough and the US Centers for Disease Control and Prevention.
Huang said: "Her strategic insights, experience and leadership in late-stage global clinical trials and the regulatory process, including post-marketing requirements, make her ideally suited for this position.
"I am very excited and am looking forward to working with Stephanie as we continue to progress iclaprim towards an approval."